Xintela AB
1XT
Company Profile
Business description
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
Contact
Medicon Village
Lund223 81
SWET: +46 462756500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
11
Stocks News & Analysis
stocks
Nvidia: Hugging Face acquisition both a wise offensive and defensive move
We think this improves Nvidia’s position within the open-source community.
stocks
Anthropic’s IPO will be huge—and risky. Here are the challenges investors should watch
Part two of a Q&A with PitchBook senior analyst Harrison Rolfes about Anthropic, the AI giant’s challenges, and how much it’s worth.
stocks
Chart of the Week: China demand for copper falls amidst record rally
Elevated copper prices raise valuation questions.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,196.00 | 54.60 | -0.59% |
| CAC 40 | 8,278.77 | 7.63 | -0.09% |
| DAX 40 | 26,046.40 | 43.08 | 0.17% |
| Dow JONES (US) | 53,414.25 | 271.86 | -0.51% |
| FTSE 100 | 10,831.09 | 0.43 | -0.00% |
| HKSE | 25,650.87 | 437.56 | 1.74% |
| NASDAQ | 26,506.99 | 77.07 | -0.29% |
| Nikkei 225 | 65,020.94 | 806.46 | 1.26% |
| NZX 50 Index | 13,974.18 | 128.00 | 0.92% |
| S&P 500 | 7,718.60 | 29.11 | -0.38% |
| S&P/ASX 200 | 9,005.90 | 64.30 | -0.71% |
| SSE Composite Index | 3,930.12 | 11.97 | -0.30% |